Tandem Diabetes Care Inc (TNDM) · Nov 5, 2026 · Earnings
Beat — Sales $283.7M vs ~$265.9M consensus; EPS $(0.10) vs ~$(0.25) consensus
Tandem Diabetes Care’s Q3 earnings beat revenue and EPS expectations as international sales and supplies surged, though U.S. pump sales declined.
Tandem is in the middle of a business-model transition: it is scaling Mobi and t:slim X2 automated insulin delivery, moving U.S. pharmacy customers toward pay-as-you-go reimbursement, expanding international direct operations, and building a next-generation tubeless Mobi pipeline. That makes this quarter mainly an execution test for growth and profitability during the transition. The company’s 2026 plan had called for $1.065–$1.085 billion of sales and 5%–6% adjusted EBITDA margin, with expected headwinds from the reimbursement and international changes.
The quarter cleared the market’s bar by a meaningful margin. Sales reached $283.7 million, about $17.8 million above the published consensus of $265.9 million, while reported loss per share of $0.10 was narrower than the roughly $0.25 expected loss. The improvement is not just cosmetic: adjusted EBITDA rose to $18.0 million, or 6% of sales, from $2.8 million a year earlier. The filing itself reports the quarter ended September 30, 2026.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Sales (Table B) | $283.7M (+13.8%) | $249.3M | ~$265.9M |
| Net loss per share (Table B) | $(0.10) | $(0.31) | ~$(0.25) |
| Adjusted EBITDA (Table D) | $18.0M | $2.8M | |
| Adjusted EBITDA margin (Table D) | 6% | 1% | |
| Free cash flow (Table D) | $(5.5M) | $4.2M |
The growth mix is encouraging but not yet broad-based. International sales increased 26%, and U.S. supplies and other revenue grew 19%, more than offsetting a 2% decline in U.S. pump sales. That suggests recurring supply revenue and overseas expansion are carrying the quarter, while the core U.S. pump franchise remains under pressure during the reimbursement transition. The broader 2026 plan likewise depended on pharmacy-channel scaling and international direct operations rather than simple unit growth.
Profitability is tracking the intended turnaround, but cash conversion still lags. A 6% adjusted EBITDA margin is at the top of the company’s existing 5%–6% full-year target, and the operating loss narrowed sharply to $2.4 million from $22.9 million. But free cash flow was negative $5.5 million in the quarter, and nine-month free cash flow was negative $39.4 million. The company is therefore demonstrating better operating leverage without yet producing consistent cash generation.
This is confirmation of the transition, not a rewritten strategy. The release does not provide a new numerical guidance reset; it points investors to the existing assumptions for 2026. The upside versus consensus is real, but the declining U.S. pump line and negative cash flow keep the result in the modestly positive category rather than making it a decisive change in the company’s story.
Bottom line: Tandem executed better than expected in Q3, with strong international and supply growth lifting both revenue and profitability. The business is moving toward its turnaround goals, but the weak U.S. pump trend and continued cash burn mean the transition is advancing—not finished. inayabay? no.
Q4 report and 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!